Agenus to Provide Third Quarter 2026 Financial Report and Development Update
Business Wire•22/10/2026•16:30 ET
0
Key Highlights
- ➤Agenus will report Q3 2026 results before market open November 5, 2026
- ➤BOT+BAL advances toward Phase 3 neoadjuvant ROBBIN trial in earlier-stage colon cancer
- ➤Armenia granted first marketing authorizations for Botvymo and Evamplix
- ➤BOT+BAL studied in over 1,500 patients across more than nine tumor types
Agenus to Provide Third Quarter 2026 Financial Report and Development Update
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the Company will release its third quarter 2026 financial results before the market opens on Thursday, November 5, 2026.
Get started
Create a free account to read the full story.